Altimmune
ALT

$7.10

1.26%

Market Cap: $505M

About: Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Employees: 59

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

54% more call options, than puts

Call options by funds: $12.4M | Put options by funds: $8.07M

15% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 40

13% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 46

4% more funds holding

Funds holding: 166 [Q1] → 172 (+6) [Q2]

26.84% less ownership

Funds ownership: 86.61% [Q1] → 59.77% (-26.84%) [Q2]

41% less capital invested

Capital invested by funds: $474M [Q1] → $282M (-$192M) [Q2]

75% less funds holding in top 10

Funds holding in top 10: 4 [Q1] → 1 (-3) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

69%

upside

Avg. target

$19.25

171%

upside

High target

$25

252%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio 31% 1-year accuracy 41 / 131 met price target	69%upside $12	Buy Reiterated	22 Aug 2024
B. Riley Securities Mayank Mamtani 54% 1-year accuracy 13 / 24 met price target	182%upside $20	Buy Reiterated	12 Aug 2024
B. Riley Securities Mayank Mamtani 54% 1-year accuracy 13 / 24 met price target	182%upside $20	Buy Reiterated	25 Jun 2024
Piper Sandler Yasmeen Rahimi 50% 1-year accuracy 14 / 28 met price target	252%upside $25	Overweight Maintained	21 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ALT published over the past 30 days

24/7 Wall Street

Five Top Obesity Stocks to Buy and Hold Long Term

Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.

Five Top Obesity Stocks to Buy and Hold Long Term

CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Altimmune, Inc. (Nasdaq:ALT), please note that the reduction of visceral adipose tissue (VAT) at Week 48 has been corrected from 25.6% to 28.3% and the reduction of subcutaneous adipose tissue has been corrected from 20.1% to 19.5%. The revised release follows:

CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related falls and fractures Visceral adipose tissue (VAT), a risk factor for cardiovascular disease, reduced by 25.6% at Week 48 GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain.

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes

GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid, Spain. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Weight loss drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide dominate the market, with Novo Nordisk leading in sales and Amgen developing a novel competitor. Altimmune's pemvidutide shows promising weight loss and lean mass preservation but faces high discontinuation rates and lacks sugar control, unlike rivals. Financially, Altimmune has a cash runway of five to six quarters, necessitating a likely dilution before their phase 3 trial completion.

Altimmune: Emerging Position In Competitive Space, But Risks Remain

3 Promising Biotech Stocks for the Long-Term: August 2024

Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE: LLY ), for example.

3 Promising Biotech Stocks for the Long-Term: August 2024

The 7 Best Under $10 Stocks to Buy in August 2024

To understand the allure of buying the best stocks under $10, it's a good idea to go back to basics. A stock's price reflects how much you pay for one dollar of a company's earnings.

The 7 Best Under $10 Stocks to Buy in August 2024

Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript

Altimmune, Inc. (NASDAQ:ALT ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan, Investor Relations Advisors-Altimmune Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Andrew Shutterly - Acting Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Liam Hiester - Piper Sandler Seema Sheoran - Evercore Omari Baruti - Goldman Sachs William Wood - B. Riley Securities Jon Wolleben - Citizens JMP Operator Good day, ladies and gentlemen, and welcome to Altimmune, Inc. Second Quarter 2024 Financial Results Conference Call.

Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript

The Motley Fool

Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year

Weight loss treatments such as Ozempic, Wegovy, Mounjaro, and Zepbound are big players in the diabetes and obesity care markets. One risk of losing weight is shedding too much muscle mass.

Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH)

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

See News Rankings